Cargando…

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan

Clinical Practice Guidelines (CPGs) play significant roles in most medical fields. However, little is known about the extent of financial Conflicts of Interest (FCOIs) related to pharmaceutical companies (Pharma) selling dermatology prescription products and dermatology CPG authors in Japan. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Murayama, Anju, Ozaki, Akihiko, Saito, Hiroaki, Sawano, Toyoaki, Shimada, Yuki, Yamamoto, Kana, Suzuki, Yosuke, Tanimoto, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553305/
https://www.ncbi.nlm.nih.gov/pubmed/33048952
http://dx.doi.org/10.1371/journal.pone.0239610
_version_ 1783593573436882944
author Murayama, Anju
Ozaki, Akihiko
Saito, Hiroaki
Sawano, Toyoaki
Shimada, Yuki
Yamamoto, Kana
Suzuki, Yosuke
Tanimoto, Tetsuya
author_facet Murayama, Anju
Ozaki, Akihiko
Saito, Hiroaki
Sawano, Toyoaki
Shimada, Yuki
Yamamoto, Kana
Suzuki, Yosuke
Tanimoto, Tetsuya
author_sort Murayama, Anju
collection PubMed
description Clinical Practice Guidelines (CPGs) play significant roles in most medical fields. However, little is known about the extent of financial Conflicts of Interest (FCOIs) related to pharmaceutical companies (Pharma) selling dermatology prescription products and dermatology CPG authors in Japan. The aims of this study were to elucidate the characteristics and distribution of payments from Pharma to dermatology CPG authors in Japan, and to evaluate the extent of transparency and accuracy in their FCOI disclosures. We analyzed the records of 296 authors from 32 dermatology CPGs published by the Japanese Dermatological Association from the beginning of 2015 to the end of 2018. Using the payment data reported by 79 Pharma between 2016–2017 in Japan, we investigated the characteristics of the CPG authors and the payments from the Pharma to them. Furthermore, we evaluated the transparency and accuracy of the FCOI disclosures of the individual CPG authors. Of the 296 CPGs authors, 269 authors (90.6%) received at least one payment from the Pharma. The total monetary value of payments for the 2-year period was $7,128,762. The median and mean monetary value of payments from the Pharma reporting were $10,281 (interquartile range $2,796 -$34,962) and $26,600 (standard deviation $40,950) for the two years combined. Of the 26 CPG authors who disclosed FCOIs due to the monies received from Pharma, only the atopic dermatitis CPG authors and the acne vulgaris CPG authors published their potential FCOIs. In Japan, most dermatology CPG authors received financial payments from Pharma. The transparency of the CPGs, as reported by the CPG authors, was inadequate, and a more rigorous framework of reporting and monitoring FCOI disclosure is required to improve the accuracy and transparency with relation to possible Conflicts of Interest.
format Online
Article
Text
id pubmed-7553305
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75533052020-10-21 Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan Murayama, Anju Ozaki, Akihiko Saito, Hiroaki Sawano, Toyoaki Shimada, Yuki Yamamoto, Kana Suzuki, Yosuke Tanimoto, Tetsuya PLoS One Research Article Clinical Practice Guidelines (CPGs) play significant roles in most medical fields. However, little is known about the extent of financial Conflicts of Interest (FCOIs) related to pharmaceutical companies (Pharma) selling dermatology prescription products and dermatology CPG authors in Japan. The aims of this study were to elucidate the characteristics and distribution of payments from Pharma to dermatology CPG authors in Japan, and to evaluate the extent of transparency and accuracy in their FCOI disclosures. We analyzed the records of 296 authors from 32 dermatology CPGs published by the Japanese Dermatological Association from the beginning of 2015 to the end of 2018. Using the payment data reported by 79 Pharma between 2016–2017 in Japan, we investigated the characteristics of the CPG authors and the payments from the Pharma to them. Furthermore, we evaluated the transparency and accuracy of the FCOI disclosures of the individual CPG authors. Of the 296 CPGs authors, 269 authors (90.6%) received at least one payment from the Pharma. The total monetary value of payments for the 2-year period was $7,128,762. The median and mean monetary value of payments from the Pharma reporting were $10,281 (interquartile range $2,796 -$34,962) and $26,600 (standard deviation $40,950) for the two years combined. Of the 26 CPG authors who disclosed FCOIs due to the monies received from Pharma, only the atopic dermatitis CPG authors and the acne vulgaris CPG authors published their potential FCOIs. In Japan, most dermatology CPG authors received financial payments from Pharma. The transparency of the CPGs, as reported by the CPG authors, was inadequate, and a more rigorous framework of reporting and monitoring FCOI disclosure is required to improve the accuracy and transparency with relation to possible Conflicts of Interest. Public Library of Science 2020-10-13 /pmc/articles/PMC7553305/ /pubmed/33048952 http://dx.doi.org/10.1371/journal.pone.0239610 Text en © 2020 Murayama et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Murayama, Anju
Ozaki, Akihiko
Saito, Hiroaki
Sawano, Toyoaki
Shimada, Yuki
Yamamoto, Kana
Suzuki, Yosuke
Tanimoto, Tetsuya
Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
title Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
title_full Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
title_fullStr Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
title_full_unstemmed Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
title_short Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
title_sort pharmaceutical company payments to dermatology clinical practice guideline authors in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553305/
https://www.ncbi.nlm.nih.gov/pubmed/33048952
http://dx.doi.org/10.1371/journal.pone.0239610
work_keys_str_mv AT murayamaanju pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT ozakiakihiko pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT saitohiroaki pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT sawanotoyoaki pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT shimadayuki pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT yamamotokana pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT suzukiyosuke pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan
AT tanimototetsuya pharmaceuticalcompanypaymentstodermatologyclinicalpracticeguidelineauthorsinjapan